SAN FRANCISCO, June 5, 2026
Structure Therapeutics Inc. announced the publication of detailed results from its Phase 2b ACCESS clinical trial evaluating aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist for obesity, in Nature Medicine. The publication coincided with an oral presentation at the American Diabetes Association (ADA) 86th Scientific Sessions. The study demonstrated dose-dependent, clinically meaningful, and statistically significant reductions in body weight, further strengthening the potential of aleniglipron as a differentiated oral obesity treatment. The company confirmed that its Phase 3 development program remains on track to begin in the third quarter of 2026, supported by efficacy, safety, and tolerability findings generated from the ACCESS program.
Significant Weight Loss and Continued Benefits Beyond 36 Weeks
Results from the Phase 2b ACCESS trial showed that all three maintenance dose groups achieved the primary endpoint and key secondary endpoints. The study demonstrated meaningful reductions in body weight among participants living with obesity or overweight with at least one weight-related comorbidity. A predefined interim analysis from the open-label extension study revealed that participants continued to lose weight beyond the initial 36-week treatment period, with no evidence of a weight-loss plateau. Patients previously treated with 45 mg, 90 mg, and 120 mg doses achieved weight reductions of 13.3%, 16.2%, and 15.3%, respectively, after a median follow-up of approximately 20 additional weeks. Improvements were also observed in several cardiometabolic risk markers, including blood pressure, waist circumference, high-sensitivity C-reactive protein (hsCRP), and HbA1c, highlighting the broader metabolic benefits of the therapy beyond weight management alone.
Favorable Safety Profile Supports Long-Term Treatment Potential
The safety findings from the ACCESS program were consistent with the well-established profile of GLP-1 receptor agonists. The most frequently reported adverse events were gastrointestinal in nature, including nausea, vomiting, and other GI-related effects. These events were generally mild to moderate in severity, decreased over time, and occurred most commonly during dose-escalation periods. Importantly, aleniglipron demonstrated a favorable tolerability profile with an overall discontinuation rate of only 10.4%, which compares favorably with many therapies in the obesity treatment landscape. Detailed analyses showed that participants who temporarily interrupted or reduced dosing were often able to restart treatment or resume dose escalation without experiencing recurring vomiting events, suggesting flexibility in treatment management and supporting the potential for sustained long-term therapy adherence.
Advertisement
Phase 3 Program Remains on Track as Obesity Pipeline Expands
Structure Therapeutics stated that the ACCESS data provide important validation for the design of its upcoming Phase 3 program. Based on the clinical findings and regulatory feedback received during End-of-Phase 2 discussions with the FDA, the company plans to initiate Phase 3 studies using a lower 2.5 mg starting dose while evaluating multiple maintenance dose levels. Company leadership expressed confidence that aleniglipron could become a transformative oral obesity therapy by combining meaningful efficacy with convenient once-daily administration. In addition to aleniglipron, Structure Therapeutics is advancing a broader obesity pipeline and is presenting additional data at ADA 2026 involving amylin-based therapies and combination treatment approaches. These programs are designed to further strengthen the company’s position in the rapidly growing obesity and metabolic disease market.
Source: Structure Therapeutics press release
